Are cancer therapies too targeted?; Teleflex snags FDA clearance for bone delivery tech; Ironwood enters PhII;

> Could cancer therapies be too targeted? Researchers at the Wellcome Trust Sanger Institute have found that narrowly targeted genetic therapies could lead treatments to fail. More

> Teleflex won FDA clearance for its vascular technology designed to deliver drugs to the inner bone. Story

> Ironwood Pharmaceuticals ($IRWD) began a Phase IIa clinical trial of its gastroesophageal reflux disease treatment using Depomed's ($DEPO) Acuform delivery technology. Release

> Researchers at the National Autonomous University of Mexico have developed a nanoparticle that targets cervical cancer cells with minimal side effects. More